Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel：An Open-label, Blank-controlled Study

NCT05664919 is registered in ClinicalTrials.gov with Sinovac Life Sciences Co., Ltd. as lead sponsor.

NCT NCT05664919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05664919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel：An Open-label, Blank-controlled Study
Lead sponsor
Sinovac Life Sciences Co., Ltd.
Phase
Not applicable
Overall status
Unknown status
Start date
October 30, 2022
Completion date
March 31, 2023
Enrollment
7,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19